Kim Jin Hwan, Park Ye-Soo, Oh Kwang Jun, Lee Sae Young, Lee Sun Young, Lee Seon Kyeong, Chung Yoon-Sok
Department of Orthopaedics, Ilsan Paik Hospital of Inje University, Goyang, South Korea.
Department of Orthopaedic Surgery, Guri Hospital, Hanyang University College of Medicine, Gyeonggi-do, South Korea.
Osteoporos Sarcopenia. 2016 Mar;2(1):45-63. doi: 10.1016/j.afos.2016.02.002. Epub 2016 Mar 2.
Little is currently known about the issues surrounding management and treatment of severe osteoporosis in South Korea. Our objective was to assess doctors' views on the perception, diagnosis, and treatment of severe osteoporosis.
Face-to-face interviews were conducted (16 February-13 March 2015) with 100 doctors (specialists in orthopedic surgery, endocrinology, neurosurgery, family medicine, or rheumatology) who treated ≥5 severe osteoporosis (T-score ≤ -2.5, plus fracture) patients per month. Respondent demographic characteristics, their perception of severe osteoporosis, its impact and treatment, and their views on current practice and unmet needs were assessed.
Of 416 doctors approached, 100 completed the survey (24% response rate). Most doctors (90%) specialized in orthopedic surgery, endocrinology, or neurosurgery. When diagnosing severe osteoporosis, most doctors (79%) considered both bone mineral density and fracture. Almost all doctors (≥91%) ranked disease impact and seriousness highly, but much fewer (≤25%) doctors thought society agreed. Most doctors (89%) had concerns with current treatments, switching treatments because of the efficacy and safety of bisphosphonates (>89%), the efficacy of selective estrogen receptor modulators (>71%), and the high cost of parathyroid hormone (>73%). Parathyroid hormone was ranked highest for efficacy and was preferentially prescribed to severe osteoporosis patients (mean 32.2% of prescriptions) compared with osteoporosis patients overall (3.7%). "Limitations with reimbursement" was the most commonly cited (76%) unmet need.
There are concerns with the safety, efficacy, and affordability of current treatments for severe osteoporosis in South Korea, as well as a perceived lack of disease awareness amongst patients and doctors.
目前对于韩国严重骨质疏松症的管理和治疗相关问题了解甚少。我们的目的是评估医生对严重骨质疏松症的认知、诊断和治疗的看法。
于2015年2月16日至3月13日对每月治疗≥5例严重骨质疏松症(T值≤ -2.5,伴有骨折)患者的100名医生(骨科手术、内分泌学、神经外科、家庭医学或风湿病学专家)进行面对面访谈。评估了受访者的人口统计学特征、他们对严重骨质疏松症的认知、其影响和治疗,以及他们对当前实践和未满足需求的看法。
在416名被邀请的医生中,100名完成了调查(回复率为24%)。大多数医生(90%)专长于骨科手术、内分泌学或神经外科。在诊断严重骨质疏松症时,大多数医生(79%)同时考虑骨密度和骨折情况。几乎所有医生(≥91%)都将疾病的影响和严重性排在很高的位置,但认为社会也认同这一点的医生要少得多(≤25%)。大多数医生(89%)对当前治疗存在担忧,由于双膦酸盐的疗效和安全性(>89%)、选择性雌激素受体调节剂的疗效(>71%)以及甲状旁腺激素的高成本(>73%)而更换治疗方法。甲状旁腺激素在疗效方面排名最高,与总体骨质疏松症患者(3.7%)相比,严重骨质疏松症患者中甲状旁腺激素的优先处方率更高(平均处方率为32.2%)。“报销限制”是最常被提及的未满足需求(76%)。
韩国目前对严重骨质疏松症的治疗在安全性、疗效和可负担性方面存在担忧,同时患者和医生对该疾病的认知也明显不足。